Dermapharm Holding SE (DMP.DE)
EUR 39.2
(1.82%)
EUR 39.2
(1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 921.66 Million EUR | 151.46% |
| 2022 | 366.53 Million EUR | -12.73% |
| 2021 | 419.98 Million EUR | -13.62% |
| 2020 | 486.18 Million EUR | 10.59% |
| 2019 | 439.63 Million EUR | 380.42% |
| 2018 | 91.51 Million EUR | -63.17% |
| 2017 | 248.46 Million EUR | 56.3% |
| 2016 | 158.96 Million EUR | -8.21% |
| 2015 | 173.18 Million EUR | 1.72% |
| 2014 | 170.26 Million EUR | 14.82% |
| 2013 | 148.28 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 911.9 Million EUR | -1.06% |
| 2024 Q2 | 912.63 Million EUR | 0.08% |
| 2023 Q2 | 988.54 Million EUR | 7.11% |
| 2023 Q3 | 978.74 Million EUR | -0.99% |
| 2023 FY | 921.66 Million EUR | 151.46% |
| 2023 Q1 | 922.96 Million EUR | 151.81% |
| 2023 Q4 | 921.66 Million EUR | -5.83% |
| 2022 Q2 | 550.46 Million EUR | 20.97% |
| 2022 Q4 | 366.53 Million EUR | -22.23% |
| 2022 FY | 366.53 Million EUR | -12.73% |
| 2022 Q1 | 455.04 Million EUR | 8.35% |
| 2022 Q3 | 471.28 Million EUR | -14.38% |
| 2021 Q1 | 460.3 Million EUR | -5.32% |
| 2021 FY | 419.98 Million EUR | -13.62% |
| 2021 Q4 | 419.98 Million EUR | -13.05% |
| 2021 Q3 | 483.02 Million EUR | -5.54% |
| 2021 Q2 | 511.35 Million EUR | 11.09% |
| 2020 Q2 | 525.56 Million EUR | 25.45% |
| 2020 Q4 | 486.18 Million EUR | -5.67% |
| 2020 Q1 | 418.95 Million EUR | -4.7% |
| 2020 Q3 | 515.42 Million EUR | -1.93% |
| 2020 FY | 486.18 Million EUR | 10.59% |
| 2019 Q3 | 458.64 Million EUR | 4.15% |
| 2019 FY | 439.63 Million EUR | 380.42% |
| 2019 Q1 | 412.73 Million EUR | 351.03% |
| 2019 Q2 | 440.35 Million EUR | 6.69% |
| 2019 Q4 | 439.63 Million EUR | -4.15% |
| 2018 Q2 | 141.4 Million EUR | -22.15% |
| 2018 FY | 91.51 Million EUR | -63.17% |
| 2018 Q4 | 91.51 Million EUR | -17.31% |
| 2018 Q3 | 110.66 Million EUR | -21.74% |
| 2018 Q1 | 181.64 Million EUR | -26.89% |
| 2017 Q4 | 248.46 Million EUR | -6.68% |
| 2017 Q3 | 266.24 Million EUR | 0.0% |
| 2017 Q1 | 3.97 Million EUR | -97.5% |
| 2017 FY | 248.46 Million EUR | 56.3% |
| 2016 FY | 158.96 Million EUR | -8.21% |
| 2016 Q4 | 158.96 Million EUR | 0.0% |
| 2015 FY | 173.18 Million EUR | 1.72% |
| 2014 FY | 170.26 Million EUR | 14.82% |
| 2013 FY | 148.28 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| MPH Health Care AG | 8.5 Million EUR | -10739.876% |
| Apontis Pharma AG | -20.8 Million EUR | 4531.077% |
| Evotec SE | 115.28 Million EUR | -699.438% |
| MERCK Kommanditgesellschaft auf Aktien | 7.95 Billion EUR | 88.42% |
| PharmaSGP Holding SE | 33.21 Million EUR | -2675.177% |
| SynBiotic SE | 3.59 Million EUR | -25565.642% |